

Date: October 1, 2026

To Listing Department, NATIONAL STOCK EXCHANGE OF INDIA LIMITED Exchange Plaza, Bandra Kurla Complex, Bandra (E), MUMBAI - 400 051 Symbol: AUROPHARMA	To The Corporate Relations Department BSE LIMITED Phiroz Jeejeebhoy Towers, 25th floor, Dalal Street, MUMBAI - 400 001 Scrip Code: 524804
---	---

Dear Sir/Madam,

Re: Disclosure under Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015.

Ref: Our letters dated July 23, 2026 and September 12, 2026.

We refer to our letter dated **July 23, 2026 and September 12, 2026**, informing that Apitoria Pharma Private Limited ("Apitoria"), a wholly owned subsidiary of the Company had acquired 100% stake in A1 Biochem Labs (India) Private Limited ("A1 Labs"), thus making it a wholly owned subsidiary of Apitoria and a step down subsidiary of the Company.

In continuation to the above and in compliance with Regulation 30 and other applicable provisions of the SEBI LODR Regulations, this is to inform that as part of the terms agreed under the definitive agreements entered into by Apitoria as part of the acquisition of A1 Biochem group, Dr. Rajendra Gadikota, former promoter of A1 Biochem group has subscribed to 89,94,500 equity shares and 2,41,05,500 Compulsory Convertibles Debentures (hereinafter together referred to as 'Securities') of A1 Labs equaling to 20% stake (on a fully diluted basis).

Pursuant to the completion of the allotment of Securities, Dr. Rajendra Gadikota is holding 20% of the stake A1 Labs on a fully diluted basis and A1 Labs accordingly ceases to be a wholly-owned subsidiary. A1 Labs continues to remain a subsidiary of Apitoria and a step down subsidiary of the Company in terms of the provisions of the Companies Act, 2013 and the SEBI Listing Regulations.

The details as required under Regulation 30 of SEBI Listing Regulations read along with applicable SEBI Master Circular SEBI/HO/CFD/PoD2/CIR/P/0155 are provided in Annexure as enclosed.

This is for your information and record.

Thanking you,

Yours faithfully,

For AUROBINDO PHARMA LIMITED

Digitally signed by ADI REDDY
BADDIGAM

Date: 2026.10.01 12:35:44 +05'30'

B. Adi Reddy

Company Secretary

Encl: as above.

AUROBINDO PHARMA LIMITED

www.aurobindo.com

(CIN : L24239TG1986PLC015190)

Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India.
Tel : +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044.

Regd. off.: Plot No. 2, Maithrivihar, Ameerpet, Hyderabad -500038 Telangana., India Tel: +91 40 2373 6370/2374 7340 Fax: +91 40 2374 1080/2374 6833
Email: info@aurobindo.com Website: www.aurobindo.com

Annexure

Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

a) The amount and percentage of the turnover or revenue or income and net worth contributed by such unit or division or undertaking or subsidiary or associate company of the listed entity during the last financial year;	Name of the entity: A1 Biochem Labs (India) Private Limited ("A1 Labs") Details as on 31st March, 2026: A1 Labs was acquired during the current financial year (July 2026). Thus it did not contribute to any revenue, income or net worth of the listed company as on 31st March, 2026
b) Date on which the agreement for sale has been entered into;	23 rd July, 2026
c) The expected date of completion of sale/disposal;	A1 Labs has received INR 9.18 Cr. for the allotment of equity shares and INR 24.62 Cr. for the allotment of Compulsory Convertible Debentures from Dr. Rajendra Gadikota and allotted 89,94,500 equity shares and 2,41,05,500 Compulsory Convertibles Debentures to him and completed all the formalities on September 30, 2026. Post allotment, Apitoria is holding 80% stake and Dr. Rajendra Gadikota is holding 20% stake in A1 Labs.
d) consideration received from such sale/disposal;	A1 Labs has received INR 9.18 Cr. for the allotment of equity shares and INR 24.62 Cr. for the allotment of Compulsory Convertible Debentures (together referred to as 'Securities').
e) Brief details of buyers and whether any of the buyers belong to the promoter/promoter group/group companies. If yes, details thereof;	Dr. Rajendra Gadikota is the former promoter of A1 Biochem Group. As part of the acquisition of A1 Biochem Group by Apitoria, it is agreed that Dr. Rajendra Gadikota will hold 20% stake (on a fully diluted basis) in A1 Labs. Further, Apitoria has the option available to acquire this 20% stake in future as per the agreed terms in the definitive agreements. Dr. Rajendra Gadikota is not related to the promoter /promoter group/group companies
f) Whether the transaction would fall within related party transactions? If yes, whether the same is done at "arm's length";	Yes, Dr. Rajendra Gadikota is a director of A1 Labs. The transaction qualifies as a related party transaction. The transaction has been undertaken at arm's length. The subscription price for the Securities has been determined based on a fair valuation report obtained from a Chartered Accountant and the offer and subscription of shares of A1 Labs has been approved by its shareholders through a special resolution.

AUROBINDO PHARMA LIMITED

www.aurobindo.com

(CIN : L24239TG1986PLC015190)

Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India.
Tel : +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044.

Regd. off.: Plot No. 2, Maithrivihar, Ameerpet, Hyderabad -500038 Telangana., India Tel: +91 40 2373 6370/2374 7340 Fax: +91 40 2374 1080/2374 6833
Email: info@aurobindo.com Website: www.aurobindo.com

g) Whether the sale, lease or disposal of the undertaking is outside Scheme of Arrangement? If yes, details of the same including compliance with regulation 37A of LODR Regulations.	Regulation 37A of LODR Regulations is not applicable as there is no sale/lease/disposal of undertaking. Further, the transaction will not fall under the definition of 'Undertaking' provided in the regulation. New Securities have been issued by A1 Labs as agreed in the terms of the definitive agreements entered into as part of acquisition of A1 Biochem Group. However, it is clarified that A1 Labs had obtained its shareholders' approval as part of the process of offer and issuance of Securities to Dr. Rajendra Gadikota (dilution of 100% stake in the subsidiary).
h) Additionally, in case of a slump sale, indicative disclosures provided for amalgamation / merger, shall be disclosed by the listed entity with respect to such slump sale.	Not applicable

Digitally signed by ADI REDDY BADDIGAM
Date: 2026.10.01 12:36:08 +05'30'